(Q36491806)

14 August 2017

1 reference

title

Treatment of invasive infections due to rare or emerging yeasts and moulds (English)

1 reference

14 August 2017

1 reference

Murat Akova

2

0 references

author name string

Gulsen Ozkaya Sahin

series ordinal

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

9

1 reference

14 August 2017

page(s)

1181-1190

1 reference

Advances and challenges in management of invasive mycoses

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Detection of Candida dubliniensis in oropharyngeal samples of Turkish HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Breakthrough zygomycosis and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Disseminated Trichosporon asahii infection in a preterm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Fatal Blastoschizomyces capitatus sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Newer antifungal therapy for emerging fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Acremonium species: new emerging fungal opportunists--in vitro antifungal susceptibilities and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Acute septic arthritis after kidney transplantation due to Acremonium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Successful treatment of Acremonium fungemia with voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Acremonium pyomyositis in a pediatric patient with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

In Vitro Activities of Three Licensed Antifungal Agents against Spanish Clinical Isolates of Aspergillus spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

The changing face of invasive fungal infections in hematopoietic cell transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Infections due to emerging and uncommon medically important fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Posaconazole: clinical pharmacology and potential for management of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Zygomycosis (mucormycosis): emerging clinical importance and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Cutaneous infection due to Scedosporium apiospermum in an immunosuppressed patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Fatal pulmonary scedosporiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Disseminated infection due to Scedosporium apiospermum in a patient with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Skin infection caused by Scedosporium apiospermum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Recurrence of Scedosporium apiospermum infection following renal re-transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Penicillium marneffei: types and drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Guidelines for treatment of candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

Disseminated Penicillium marneffei infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1181

10.1517/14656566.7.9.1181

21 January 2018

Identifiers

DOI

1 reference

release_xzaabgjv6zho7e7xpxo4xsym5q

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xzaabgjv6zho7e7xpxo4xsym5q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference